67-第67章 多发性肌炎和皮肌炎

可乐加水

随着免疫抑制治疗的出现，特发性炎性肌病的预后不断改善。皮质激素出现前成人特发性炎性肌病的5年生存率为60%,1947一1968年为 68%，近几年为 80 。用通信方式对1986一1998年的59例特发性炎性肌病病人进行了随访，一年生存率为90%,2-5年生存率为80%。前5年共死亡12例，其中死于肺内感染5例，肺纤维化4例，肿瘤3例。发病前3年病情较重，激素用量大，激素减量或停用时病情易复发;发病5年后病情趋于稳定，有三分之一的病人脱离激素，病情仍保持稳定。我们的病人多数较重，病例也较少，因此，这些统计数字与实际情况可能会有差异，它只是在一定程度上也反映了一种趋向。除使用免疫抑制剂外，早诊断早治疗，以及有效控制并发症也有助于预后的改善。
2 e" \' ^" o9 j4 H% M                                                                                                                (吴东海)
, Y% J. R( q2 o      参考文献：

# Y% V, H0 C7 I  v* B       马丽，王丽英，侯广庆，等 皮肌炎多发性肌炎59例随访.中华风湿病学杂志，5:59一61   
3 [# b. ^6 K; f5 n
      Askanas V, Engel W N. Sporadic inclusion-body myositisand hereditary inclusion body myopathies: current concepts of di-agnosis and pathogenesis. Curr Opin Rheumatol, 1998.10:530  
- s$ V# ^8 K; `( k: m0 \; _
1 a- M2 c. {) E" i5 _      Ausem M G E M, Lochman P, van Diggelen O P, et al. Adiagnostic test for adult-onset glycogen storage disease type 11.Neurology, 1999.52:851  

      Behrens L, Bender A, Johnson M A, et al. Cytotoxic mech-anisms in inflammatory myopathied co-expression of Fas and pro-tective Bcl-2 in muscle fibers and inflammatory cells. Brain,1997. 120:929

      Dalakas M C,Dambrosia J M. A controlled trial of high-doseintravenous immuneglobulin infusions as treatment for dermato-myositis. N Engl J Med, 1993. 329:1993一2000

      Fafalak R G, Peterson M G, Kagen L J. The strength inpolymyositis and dermatomyositis: best outcome in patients treat-ed early. J Rheumatol, 1994.21:643一648

5 R- R0 b/ w. d      Fyher I-M, Moslemi A-R, Mosavia A, et al. Oligoexpres-sion in muscle infiltrating T cells in inclusion body myositis. JNeuroimmunol 1997.79:185

2 w# a  G8 p2 O1 ~0 Z) _: K0 s! @      Garlepp M J, Mastaglia F L. Inclusion body myositis. JNeurol Neurosurg Psychiatry, 1996. 60:251一258
      Garton M J, Isenberg D A. Clinical features of lupus myosi-tis versus idiopathic myositis: A review of 30 cases.  Br JRheumatol, 1997.36:1067

      Goebels N, Michaelis D, Engelhardt M, et al. Differentialexpression of perforin in muscle-infiltrating T cells in polymyositisand dermatomyositis. J Clin Invest, 1996.97:2905  
7 D6 \5 z& {$ q$ g) p5 ~
4 ~# ]  M- j( v# E9 S( l% ]      Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, et al. Car-diac manifestations in dermato-polymyositis. Clin Exp Rheumatol1996. 14:373
  C2 {7 Q3 Y# F' V1 E% F( L
: Y- C2 {) M( u) g. d      Mantegazza R, Bernasconi P, Confalonieri P, et al. Inflam-matory myopathies and systemic disorders: a review of im-munopathogenetic mechanisms and clinical features. J Neurol,1997. 244:277
6 t, ^' O/ h& a6 ^% D" Z' z4 ~
      Marie 1, Horton P-Y, Hachulla E, et al. Pulmonary in-volvement in polymyositis and in dermatomyositis. J Rheumatol,1998. 25:1336
: @, ^  N. M# ^+ |
      Naparstek Y, Plotz P H. The role of autoantibodies in au-toimmune disease. Ann Rev Immunol, 1993.11:79一104   
$ t8 ~+ V9 d  F) C+ F+ a6 N
3 f& Z6 M5 @( s* t$ k      Pascuzzi R M. Drugs and toxins associated with myopathies.Curr Opin Rheumatol, 1998.10:511   

7 q. |( d. C+ Y, H* Y) r      Pickering M C, Walport M J. Eosinophilic myopathic syn-dromes. Curr Opin Rheumatol,1998. 10:504

* h8 B- g1 v6 C, e+ z# l      Plotz P H, Rider L G，Targoff I N, et al. NIH conference.Myositis:  immunologic contributions to understanding cause,pathogenesis and therapy. Ann Intern Med, 1995-122: 715一724

      Robert L. Wortmann. Inflammatory Diseases of Muscle andOther Myopathies. Kelley’s Textbook of Rheumatology, 6thEd，W. B. Saunders Company. 2001  

+ y# y/ T) ^2 e/ ]- p7 X( y) ?, d8 Z      Sieb J P, Ries F, Traber, et al. Recurrent focal myositis.Muscle Nerve, 1997. 20:1205
' q* R8 j- i% V. e4 g0 b4 l
. ?) C  R( F' G( a! Y! ?/ I1 F      Targoff I N, Miller F W, Medsger T A Jr, et al. Classifica-tion criteria for the idiopathic inflammatory myopathies. CurrOpin Rheumatol, 1997.9:527  

      Villalba L, Hicks J E, Adams E M, et al. Treatment of re-fractory myositis. Arthritis Rheum 1998. 41:392  
2 x6 [) F' o) I; }: o5 V" ^" |" m3 q! M
( I6 j3 n' h3 B& ], m, b      Whitemore S E, Watson R, Rosenshein N B, et al. Der-matomyositis sine myositis:  Association with malignancy.  JRheumatol, 1996.23:1010
2 b$ d2 ]3 T' T% b4 q: O! g
      Zieglschmid M E, Pandya A G, Cohen S B, et al. Treat-ment of dermatomyositis with methotrexate. J Am Acad Derma-tol, 1995.32:754一757